There are times when treating the numbers makes sense because it is fairly well established what different numbers mean clinically. Such is not the case here.
Synopsis of the most recent guidelines here. Click each question for their conclusion. Basic theme repeated is
-
“In this population, 25(OH)D levels that provide outcome-specific benefits have not been established in clinical trials.
-
The panel suggests against (a) routine screening for a 25(OH)D level to guide decision-making (i.e., vitamin D vs no vitamin D) and (b) routine follow-up testing for 25(OH)D level to guide vitamin D dosing.”
More detail than most would want here:
https://academic.oup.com/edrv/article/45/5/625/7659127
It is very unclear if the association of low vitamin D stores (as reflected by 25OH Vitamin D levels) is cause or effect. The benefits of supplementation are solidly seen only in a few specific circumstances (e.g. infirm elderly at high risk of fractures when given with a calcium supplement as well) and otherwise are mostly “potential” benefits.
Screening broadly adds up as a significant public health expense without evidence that it improves health outcomes. A recommendation for screening generally has to pass the other way, defined benefits that outweigh the cost.
Supplementation of an RDA’s worth (fortified food or otherwise) OTOH is low cost low risk option that even possible benefit is, to the expert panel, worth doing.
Specific conditions and circumstances are exceptions but not the rule.